123 related articles for article (PubMed ID: 21427563)
1. A tumor-penetrating peptide modification enhances the antitumor activity of endostatin in vivo.
Hai-Tao Z; Hui-Cheng L; Zheng-Wu L; Chang-Hong G
Anticancer Drugs; 2011 Jun; 22(5):409-15. PubMed ID: 21427563
[TBL] [Abstract][Full Text] [Related]
2. Addition of integrin binding sequence to a mutant human endostatin improves inhibition of tumor growth.
Yokoyama Y; Ramakrishnan S
Int J Cancer; 2004 Oct; 111(6):839-48. PubMed ID: 15300795
[TBL] [Abstract][Full Text] [Related]
3. Addition of an aminopeptidase N-binding sequence to human endostatin improves inhibition of ovarian carcinoma growth.
Yokoyama Y; Ramakrishnan S
Cancer; 2005 Jul; 104(2):321-31. PubMed ID: 15952188
[TBL] [Abstract][Full Text] [Related]
4. Tat PTD-endostatin: A novel anti-angiogenesis protein with ocular barrier permeability via eye-drops.
Zhang X; Li Y; Cheng Y; Tan H; Li Z; Qu Y; Mu G; Wang F
Biochim Biophys Acta; 2015 Jun; 1850(6):1140-9. PubMed ID: 25662072
[TBL] [Abstract][Full Text] [Related]
5. Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein.
Cho HM; Rosenblatt JD; Kang YS; Iruela-Arispe ML; Morrison SL; Penichet ML; Kwon YG; Kim TW; Webster KA; Nechustan H; Shin SU
Mol Cancer Ther; 2005 Jun; 4(6):956-67. PubMed ID: 15956253
[TBL] [Abstract][Full Text] [Related]
6. Tat PTD-Endostatin-RGD: A novel protein with anti-angiogenesis effect in retina via eye drops.
Li Y; Li L; Li Z; Sheng J; Zhang X; Feng D; Zhang X; Yin F; Wang A; Wang F
Biochim Biophys Acta; 2016 Oct; 1860(10):2137-47. PubMed ID: 27233450
[TBL] [Abstract][Full Text] [Related]
7. An RGD-Modified Endostatin Peptide Expressed at E. coli Shows Anti-Tumor Activity In vivo.
Zhang HT; Li HC; Li ZW; Guo CH; Chen YJ
Protein Pept Lett; 2011 Jun; ():. PubMed ID: 21675950
[TBL] [Abstract][Full Text] [Related]
8. Genetically engineered endostatin-lidamycin fusion proteins effectively inhibit tumor growth and metastasis.
Jiang WG; Lu XA; Shang BY; Fu Y; Zhang SH; Zhou D; Li L; Li Y; Luo Y; Zhen YS
BMC Cancer; 2013 Oct; 13():479. PubMed ID: 24128285
[TBL] [Abstract][Full Text] [Related]
9. Targeted delivery of an antibody-mutant human endostatin fusion protein results in enhanced antitumor efficacy.
Shin SU; Cho HM; Merchan J; Zhang J; Kovacs K; Jing Y; Ramakrishnan S; Rosenblatt JD
Mol Cancer Ther; 2011 Apr; 10(4):603-14. PubMed ID: 21393427
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of ovarian cancer by RGD-P125A-endostatin-Fc fusion proteins.
Jing Y; Lu H; Wu K; Subramanian IV; Ramakrishnan S
Int J Cancer; 2011 Aug; 129(3):751-61. PubMed ID: 21225621
[TBL] [Abstract][Full Text] [Related]
11. Effects of endostatin-vascular endothelial growth inhibitor chimeric recombinant adenoviruses on antiangiogenesis.
Pan X; Wang Y; Zhang M; Pan W; Qi ZT; Cao GW
World J Gastroenterol; 2004 May; 10(10):1409-14. PubMed ID: 15133844
[TBL] [Abstract][Full Text] [Related]
12. The effect of intracellular protein delivery on the anti-tumor activity of recombinant human endostatin.
Lim J; Duong T; Lee G; Seong BL; El-Rifai W; Ruley HE; Jo D
Biomaterials; 2013 Aug; 34(26):6261-71. PubMed ID: 23714245
[TBL] [Abstract][Full Text] [Related]
13. The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization.
Olsson AK; Johansson I; Akerud H; Einarsson B; Christofferson R; Sasaki T; Timpl R; Claesson-Welsh L
Cancer Res; 2004 Dec; 64(24):9012-7. PubMed ID: 15604266
[TBL] [Abstract][Full Text] [Related]
14. Angiosuppressive and angiostimulatory effects exerted by synthetic partial sequences of endostatin.
Morbidelli L; Donnini S; Chillemi F; Giachetti A; Ziche M
Clin Cancer Res; 2003 Nov; 9(14):5358-69. PubMed ID: 14614021
[TBL] [Abstract][Full Text] [Related]
15. Tumor-penetrating iRGD peptide inhibits metastasis.
Sugahara KN; Braun GB; de Mendoza TH; Kotamraju VR; French RP; Lowy AM; Teesalu T; Ruoslahti E
Mol Cancer Ther; 2015 Jan; 14(1):120-8. PubMed ID: 25392370
[TBL] [Abstract][Full Text] [Related]
16. Studies on the structure-activity relationship of endostatin: synthesis of human endostatin peptides exhibiting potent antiangiogenic activities.
Chillemi F; Francescato P; Ragg E; Cattaneo MG; Pola S; Vicentini L
J Med Chem; 2003 Sep; 46(19):4165-72. PubMed ID: 12954068
[TBL] [Abstract][Full Text] [Related]
17. An RGD-modified endostatin-derived synthetic peptide shows antitumor activity in vivo.
Xu HM; Yin R; Chen L; Siraj S; Huang X; Wang M; Fang H; Wang Y
Bioconjug Chem; 2008 Oct; 19(10):1980-6. PubMed ID: 18800818
[TBL] [Abstract][Full Text] [Related]
18. Cholesterol sequestration by nystatin enhances the uptake and activity of endostatin in endothelium via regulating distinct endocytic pathways.
Chen Y; Wang S; Lu X; Zhang H; Fu Y; Luo Y
Blood; 2011 Jun; 117(23):6392-403. PubMed ID: 21482707
[TBL] [Abstract][Full Text] [Related]
19. Effect of RGD-4C position is more important than disulfide bonds on antiangiogenic activity of RGD-4C modified endostatin derived synthetic polypeptide.
Yin R; Zheng H; Xi T; Xu HM
Bioconjug Chem; 2010 Jul; 21(7):1142-7. PubMed ID: 20515045
[TBL] [Abstract][Full Text] [Related]
20. Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer.
Beck MT; Chen NY; Franek KJ; Chen WY
Cancer Res; 2003 Jul; 63(13):3598-604. PubMed ID: 12839947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
